Catherine Wood 調整 Beam Therapeutics 的立場，反映投資組合調整

投資界的知名人物 Catherine Wood（Trades、Portfolio）於 2024 年 9 月 30 日減少了 Beam Therapeutics Inc（BEAM、Financial）的倉位，這是一項重大舉措。

Catherine Wood (Trades, Portfolio) decreased her position in Beam Therapeutics Inc (NASDAQ:BEAM) by 1,095,040 shares on September 30, 2024, according to a recent SEC filing.

根據最近向 SEC 提交的文件，Catherine Wood（交易、投資組合）於 2024 年 9 月 30 日將其在 Beam Therapeutics Inc（納斯達克股票代碼：BEAM）的持股減少了 1,095,040 股。

Following the transaction, Wood now holds a total of 6,531,099 shares in the biotechnology company, which is known for its base editing technology. This adjustment to her portfolio aligns with her strategy of identifying disruptive innovation opportunities.

交易完成後，伍德目前總共持有這家以鹼基編輯技術聞名的生技公司6,531,099股股票。她對投資組合的這項調整符合她尋找顛覆性創新機會的策略。

The trade was executed at a price of $24.5 per share, and Beam Therapeutics now comprises 1.42% of Wood's portfolio, as of the last filing. The stock has seen a 7.71% gain since the transaction, and is currently trading at $26.39.

此交易的執行價格為每股 24.5 美元，截至上次備案，Beam Therapeutics 目前佔 Wood 投資組合的 1.42%。自交易以來，該股已上漲 7.71%，目前交易價格為 26.39 美元。

Investors should note that the stock is currently trading at $26.39, which is notably higher than the GF Value of $18.95. This indicates that the stock may be overvalued.

投資者應注意，該股目前交易價格為 26.39 美元，明顯高於 18.95 美元的 GF 值。這表明該股可能被高估。

Moreover, the stock has a GF Score of 54/100, which suggests poor future performance potential. However, the company has achieved an impressive 1,598% revenue growth over the past three years.

此外，該股票的 GF 分數為 54/100，這表明未來業績潛力不佳。然而，該公司在過去三年中實現了令人印象深刻的 1,598% 收入成長。

Beam Therapeutics is a biotechnology company that specializes in genetic medicines using base editing technology. This innovative approach allows for precise genetic modifications without causing double-stranded breaks in DNA.

Beam Therapeutics 是一家生物技術公司，專門利用鹼基編輯技術開發基因藥物。這種創新方法可以實現精確的基因修飾，而不會導致 DNA 雙股斷裂。

The company's key programs include BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201. With a market capitalization of $2.19 billion, Beam Therapeutics is at the forefront of genetic medicine development.

該公司的主要項目包括BEAM-101、ESCAPE、BEAM-302、BEAM-301和BEAM-201。 Beam Therapeutics 的市值為 21.9 億美元，處於遺傳醫學發展的前沿。

Catherine Wood, the founder of ARK, established in 2014, is known for her focus on disruptive innovation in her investment strategy.

ARK 成立於 2014 年，創辦人凱瑟琳伍德 (Catherine Wood) 以其投資策略中註重顛覆性創新而聞名。

Her firm's mission is to identify and capitalize on these opportunities, with a unique approach that spans sectors, market capitalizations, and geographies. Some of the notable holdings include Tesla Inc (NASDAQ:TSLA), Block Inc (NYSE:SQ), Roku Inc (NASDAQ:ROKU), Roblox Corp (NYSE:RBLX), and Coinbase Global Inc (NASDAQ:COIN).

她的公司的使命是透過跨行業、市值和地理的獨特方法來識別和利用這些機會。一些著名的持股包括特斯拉公司（納斯達克股票代碼：TSLA）、Block Inc（NYSE：SQ）、Roku Inc（納斯達克股票代碼：ROKU）、Roblox Corp（紐約證券交易所代碼：RBLX）和Coinbase Global Inc（納斯達克股票代碼：COIN）。

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

本文由 GuruFocus 生成，旨在提供一般見解，並非量身訂做的財務建議。我們的評論植根於歷史數據和分析師預測，採用公正的方法，無意作為具體的投資指導。它不提出購買或剝離任何股票的建議，也不考慮個人投資目標或財務狀況。我們的目標是提供長期的、基本數據驅動的分析。請注意，我們的分析可能不包含最新的、對價格敏感的公司公告或定性資訊。 GuruFocus 不持有本文提及的股票的部位。